Roche Holding AG Ordinary Shares new ROP
News
FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
Roche Drug Approved in the U.S. for Rare Autoimmune Disease
Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug
Roche CEO Signals New Wave of Drugs to Fuel Growth Next Year, Beyond — Update
Roche Posts Higher Sales on Growth Across Pharma, Diagnostics Units
Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion — Update
Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio
Roche Gets FDA Approval for Enspryng to Treat Thyroid Eye Disease
FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro
Roche Licenses Obesity Therapy From China's Rona in Up to $1.2 Billion Deal
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
